T
he global population is aging as life expectancy increases. That means not only is demand for healthcare rising, but the very nature of that care is changing. In this interview, the CEO of Swiss pharmaceutical company Novartis, Joseph Jimenez, discusses with McKinsey’s Rik Kirkland issues including the emerging need for regenerative medicine, how digitization is driving innovation, and why Novartis is shifting to an outcomes-based approach for patient treatments. An extended and edited transcript of Jimenez’s remarks follows.
